Table 2 Significantly changing nuclear proteins in AML patient blasts

From: Integrated nuclear proteomics and transcriptomics identifies S100A4 as a therapeutic target in acute myeloid leukemia

Gene symbol

Gene name

Frequency

Fold change (AML vs. CD34+)a

Frequency × fold change≠

Abnormally expressed in AMLb

HMGA2

High mobility group protein HMGI

14

−6.0

84.7

Yes

ANXA1

Annexin A1

11

6.3

69.6

Yes

PTRF

Polymerase I and transcript release factor

11

−5.7

63.4

Yes

S100A4

Protein S100-A4

11

5.5

60.5

Not reported

LSP1

Lymphocyte-specific protein 1

13

−4.2

54.8

Yes

MYEF2

Myelin expression factor 2

10

−5.4

54.1

Yes

MPO

Myeloperoxidase

9

5.3

48.4

Yes

ANXA4

Annexin A4

11

4.20

46.2

Yes

S100A6

Protein S100-A6

11

3.89

42.8

Not reported

FLNB

Filamin B

13

−3.3

42.7

Yes

  1. The top 10 most significant protein changes are shown based on the ≠product of frequency of observation and magnitude of change (independent of direction of change). At a minimum, proteins must have significantly changed ± > 2 fold between normal CD34+ control and AML in at least 5 of the 15 patients (Frequency) derived from Supplementary Table S2
  2. aCalculation based solely on patients where a significant change was observed to derive the average fold change of AML vs. CD34+ normal control. Positive fold change values are upregulated in AML vs. control. Negative values downregulated in AML vs. control
  3. bLiterature references for proteins reported as an abnormality in AML are provided in Supplementary Table S6
Back to article page